secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001723128-22-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal reports Q1 2022 net revenue $498M (+1% YoY), GAAP net loss $2M, adj. EPS $0.12
--------------------------------------------------------------------------------

- Net revenue $498M vs $493M in Q1 2021; driven by generics and AvKARE distribution, partially offset by Zomig loss of exclusivity.
- GAAP net loss $2M ($0.01 diluted loss per share) vs net income $7M in Q1 2021.
- Adjusted EBITDA $100M including $5M R&D milestone expense; adjusted diluted EPS $0.12.
- Company maintains 2022 full-year outlook; highlights FDA approvals for two biosimilars and Saol Baclofen acquisition.
- Growth strategy focused on biosimilars, injectables, and advancing R&D pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312822000012/0001723128-22-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312822000012/amrx-20220504.htm
  HTML page:      https://secwatch.observer/filing/0001723128-22-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer